Sort
15,273 grants matching “antimicrobial resistance”
Proteolysis and Skin Antimicrobials
$306,861Richard L Gallo · Veterans Medical Research Fdn/San Diego · R01 · FY2007 · AR
Genomics-Accelerated Discovery and Biosynthesis of Phosphonic Acid Natural Products
$306,791Kou-San Ju · Ohio State University · R01 · FY2020 · GM
Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens
$306,500Jay Edward Wrobel · Fox Chase Chemical Diversity Center, Inc · R41 · FY2022 · AI
PA21259, SBIR, Phase I, Development of a rapid, direct from blood, phenotypic antimicrobial susceptibility assay
$306,500Lorenzo Damico · Aincobio Llc · R43 · FY2023 · IP
A Single Dose Therapy to Treat Drug Resistant Gonorrhea
$306,497Laurene Wang · Aimmax Therapeutics, Inc. · R44 · FY2024 · AI
Optimization and Characterization of Novel Antifungal Peptides
$306,486Kara S Keedy · Aimmax Therapeutics, Inc. · R43 · FY2022 · AI
Nasal carriage of S. aureus: host-pathogen interactions
$306,483Alexander M Cole · University Of Central Florida · R01 · FY2009 · AI
Nasal carriage of S. aureus: host-pathogen interactions
$306,483Alexander M Cole · University Of Central Florida · R01 · FY2008 · AI
Nanoparticle decoys for treating infections with enterotoxin-producing pathogens
$306,459Lars Eckmann · University Of California, San Diego · R21 · FY2016 · AI
Optimization and Characterization of Novel Antifungal Peptides
$306,408Kara S Keedy · Aimmax Therapeutics, Inc. · R43 · FY2023 · AI
MOLECULAR AND FUNCTIONAL ANALYSES OF THE PMRA/PMRB REGULATORY SYSTEM
$306,330Eduardo A. Groisman · Yale University · R01 · FY2013 · AI
Reducing infections and blockage associated with long-term implantation of ventriculoperitoneal and related shunts
$306,315Kenneth Wynne · Wynnvision, Llc · R44 · FY2025 · NS
Detecting and Monitoring Implant Infection Using X-ray Excited Luminescence Chemical Imaging (XELCI)
$306,311Jeffrey N Anker · Clemson University · R01 · FY2016 · AR
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** THE CATFISH INDUSTRY IS THE LARGEST SECTOR OF U.S. AQUACULTURE, WITH MOST PRODUCTION IN MISSISSIPPI AND WEST ALABAMA. CATFISH PRODUCERS FACE MAJOR DISEASE ISSUES DUE TO BACTERIAL PATHOGENS, NAMELY VIRULENTAEROMONAS HYDROPHILA(VAH),EDWARDSIELLASPP., AND COLUMNARIS-CAUSING BACTERIA (FLAVOBACTERIUMSPP.). MOST PRODUCERS RELY HEAVILY ON ANTIBIOTICS TO TREAT THESE DISEASES, WHICH ARE COSTLY AND PRESENT AN INHERENT RISK OF DEVELOPING ANTIMICROBIAL RESISTANCE OVER TIME, AS THE AQUACULTURE INDUSTRY IS CURRENTLY LIMITED TO JUST THREE OPTIONS. THERE HAS BEEN AN INCREASED INTEREST IN PROBIOTIC APPLICATIONS TO REDUCE ANTIBIOTIC DEPENDENCY AND ENHANCE FISH HEALTH. ONE SUCH PROBIOTIC, AP193, DEMONSTRATES EFFICACY AGAINST VAH INFECTION DUE TO METABOLITE PRODUCTION OF DIFFICIDIN. FURTHER, AN INACTIVATED, MUTANT VAH VACCINE HAS BEEN DEVELOPED AT AU AND PROVIDES PROTECTION WHEN ADMINISTERED VIA ORAL DELIVERY. APPLYING THESE PREVENTATIVE AND ALTERNATIVE APPROACHES WILL PROVIDE PRODUCERS WITH TOOLS TO COMBAT ON-FARM VAH OUTBREAKS, BUT WE BELIEVE BOTH APPROACHES CAN BE SYNERGISTICALLY OPTIMIZED. TO ACCOMPLISH THIS, OUR CURRENT PROJECT AIMS TO: 1) GENERATE AN OPTIMIZED PROBIOTIC STRAIN FOR ENHANCED METABOLITE PRODUCTION; 2) EVALUATE A COMBINATION OF PROBIOTIC + VACCINE FEEDING TO BOLSTER PROTECTION IN CATFISH AND FURTHER EXPLORE THE IMMUNE RESPONSE USING A TILAPIA ORAL GAVAGE CHALLENGE MODEL; AND 3) DISCERN THE CROSS-PROTECTIVE ABILITY OF THESE TWO APPROACHES IN PROTECTING AGAINST DIFFERENT VAH CLADES IN HYBRID AND CHANNEL CATFISH. THIS SPECIAL RESEARCH GRANTS FOR AQUACULTURE PROJECT WILL BENEFIT CATFISH PRODUCERS BY PROVIDING PREVENTATIVE OPTIONS FOR VAH MANAGEMENT THAT CAN BE ADMINISTERED AT THE POND LEVEL.
$306,293Auburn University · · FY2024 · National Institute of Food and Agriculture
PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TB
$306,226Shashi Kant · University Of Texas Hlth Ctr At Tyler · R01 · FY2022 · HD
PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TB
$306,226Shashi Kant · University Of Texas Hlth Ctr At Tyler · R01 · FY2023 · HD
PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TB
$306,226Shashi Kant · University Of Texas Hlth Ctr At Tyler · R01 · FY2021 · HD
Oral Mucosal Immunity in Vulnerable HIV Infected Populations
$306,180Aaron Weinberg · Case Western Reserve University · P01 · FY2012 · DE
Genomics-Accelerated Discovery and Biosynthesis of Phosphonic Acid Natural Products
$306,010Kou-San Ju · Ohio State University · R01 · FY2021 · GM
STRUCTURE-BASED TUBERCULOSIS DRUG DESIGN TARGETED AT ACYL-COA CARBOXYLASE
$306,000Shiou-Chuan Tsai · University Of California-Irvine · R01 · FY2010 · AI
Drs2p Function in Clathrin-coated Vesicle Budding
$305,915Todd R Graham · Vanderbilt University · R01 · FY2007 · GM
Molecular mechanisms of gasdermins and pyroptosis
$305,900Tsan Sam Xiao · Case Western Reserve University · R01 · FY2021 · GM
Regulation and Physiological Roles of Translational Fidelity
$305,874Jiqiang Ling · Univ Of Maryland, College Park · R35 · FY2020 · GM
Molecular Detection of Blood Stream Infections in Women with Gynecologic Cancer
$305,791Jeanne Ann Jordan · George Washington University · R01 · FY2012 · AI
Molecular Detection of Blood Stream Infections in Women with Gynecologic Cancer
$305,791Jeanne Ann Jordan · George Washington University · R01 · FY2011 · AI